|
Mutation Information
|
Mutation Site
|
M184V |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Relevant Drug
|
emtricitabine (FTC) |
|
Country
|
South Africa |
Literature Information
|
PubMed PMID
|
33247553
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2020 |
|
Journal
|
Journal of the International AIDS Society |
|
Title
|
Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial. |
|
Author
|
Celum CL,Gill K,Morton JF,Stein G,Myers L,Thomas KK,McConnell M,van der Straten A,Baeten JM,Duyver M,Mendel E,Naidoo K,Dallimore J,Wiesner L,Bekker LG |
|
Evidence
|
Her genotype resistance assay showed the M184V mutation indicating resistance to emtricitabine, and she was virally suppressed three months after initiation of tenofovir, emtricitabine and efavirenz. None of the remaining 199 participants seroconverted during 176 person-years of follow-up for an HIV incidence of zero (95% CI 0.0, 3.0).
|
|
|
HIV Mutation Detail Information